1 active not recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Pancytopenia: new trials by email Literature Review of Pancytopenia trials Research Report on Pancytopenia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia Cohort 1: hATG, CsA, EPAG Day 14 to Month 6, Cohort 2: hATG, CsA, EPAG Day 14 to Month 3, Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6 - Severe Aplastic Anemia | Phase 1 / Phase 2 | Active not recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 207 | 2012-07-02 | 2026-04-13 |
Anemia, Aplastic (1) · Autoimmune Diseases (1) · Thrombocytopenia (1)
Anemia (1) · Blood Platelet Disorders (1) · Bone Marrow Diseases (1) · Bone Marrow Failure Disorders (1) · Cytopenia (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1)
Cyclosporine (1) · eltrombopag (1)
National Heart, Lung, and Blood Institute (NHLBI) (1)
United States (1)
PMID 26354756, PMID 29419434, PMID 29674506, PMID 29958797, PMID 33410523, PMID 33910334, PMID 34525188, PMID 34724566